The Janus Pharma Insights

Episode 14. Nephrology is a high-value, specialist-driven franchise segment — but most distributors don't know what to specifically check before signing with any company. This episode covers the four things that actually matter: dedicated nephrology product range, DCGI approval for nephrology indications, cold chain capability for temperature-sensitive molecules, and division-specific monopoly rig...

Episode 13. Biapenem is a carbapenem antibiotic — the class doctors reach for when other antibiotics fail. This episode answers directly: what Biapenem is, how it works by blocking bacterial cell wall synthesis, what infections it treats — septicemia, hospital-acquired pneumonia, complicated UTIs, intra-abdominal infections — and what makes it different from other carbapenems like Meropenem. Full...

Episode 12. Between ₹60,000 and ₹1,75,000 — that's the realistic investment to start a general range PCD pharma franchise in India in 2026. This episode breaks down exactly where that money goes, what profit margins to expect across antibiotics, antacids, analgesics, and nutraceuticals, what documents you actually need, and how to choose the right franchise partner. Full investment guide at Janus...

Episode 11. PCOS, infertility, prenatal care, menopause management — women's healthcare in India is driven by chronic, long-term conditions that generate consistent repeat prescriptions year-round. This episode covers why the gynae PCD franchise segment is one of the most consistently profitable in Indian pharma, what the full product range looks like, and what to check before signing with any com...

Episode 10. Most pharma brands in India don't own a factory — they partner with a WHO-GMP certified contract manufacturer and focus on building their brand. This episode covers what Janus Biotech's third party manufacturing actually offers: a wide product range across tablets, capsules, injectables, syrups, nutraceuticals, and herbal formulations, flexible batch sizes, full DCGI-approved documenta...

Episode 9. Most skincare brands choose a niacinamide serum manufacturer based on price — and most of them regret it. This episode covers what actually matters when evaluating a supplier: formulation expertise, certifications, stability testing standards, MOQ flexibility, and communication. Based on Janus Biotech's guide to choosing the best niacinamide serum supplier — covering everything from R&a...

Episode 8. India's GERD market is projected to reach ₹2,245 crore by 2033, and Vonoprazan is capturing a growing share of it — backed by Torrent, Lupin, Dr Reddy's, Zydus, and Mankind all launching their own brands. This episode covers the future of Vonoprazan PCD pharma business in India through 2027 — falling prices, growing combination products, and why tier-2 and tier-3 cities are where the re...

Episode 7. Six episodes in and we've been deep in Vonoprazan — today we step back and look at Janus Biotech as a whole. From a single pharmacy in 1957 to one of North India's fastest growing pharma companies, with 3500+ products, 1500+ business partners, and 17 specialized divisions covering gastro, cardiac, gynecology, derma, pediatrics, nutraceuticals, orthopedics and more. This episode covers w...

Vonoprazan is reshaping how India treats acid reflux, working faster and controlling night-time acid breakthrough better than older PPIs like pantoprazole or omeprazole — which is why major players from Torrent to Mankind have launched their own versions within months of each other. In this episode, we look at where the Vonoprazan PCD opportunity is headed through 2027, from falling prices as excl...

Episode 5. Vonoprazan PCD franchise is gaining traction — but is it the right move for your business? This episode breaks down the honest case: chronic repeat prescriptions, early mover advantage in a growing category, and a versatile product range covering GERD, nausea, and H. pylori eradication. Full details in Janus Biotech's Vonoprazan PCD, HP kit and Domperidone guide . If you're just joining...

Episode 4. We go deeper into the Vonoprazan product range — covering two combinations that are gaining serious traction with doctors right now. The Vonoprazan HP kit and Vonoprazan Domperidone guide by Janus Biotech covers H. pylori eradication therapy, chronic GERD management, and why these combinations make a strong case for any gastro franchise portfolio. We also cover the Vonoprazan 10mg and 2...

Episode 3. Vonoprazan is already gaining ground with doctors — but the real opportunity is on the distribution side. This episode breaks down why a Vonoprazan PCD pharma franchise makes business sense right now, from repeat demand driven by chronic GERD patients to monopoly rights and strong profit margins. We also cover the HP kit for H. pylori therapy and the Vonoprazan Domperidone combination —...

In Episode 2 of The Janus Pharma Insights, we explore Vonoprazan — a potassium-competitive acid blocker (P-CAB) offering fast, lasting relief for GERD, reflux esophagitis, and peptic ulcers. We look at why it's gaining traction with healthcare providers and how Janus Biotech supplies high-grade Vonoprazan 10 mg and 20 mg tablets to distributors and pharmacies across India. Looking for a reliable s...

In this episode of The Janus Pharma Insights, we explore the rise of niacinamide serum manufacturing in India and why skincare brands are rapidly investing in niacinamide-based products. From growing consumer awareness and dermatologist-backed skincare trends to private label cosmetic manufacturing and third-party serum production, this podcast discusses the factors driving demand in the Indian sk...